## Alaska Medicaid Pharmacy and Therapeutics Committee Meeting January 17, 2025

(Please note, this meeting will be available via teleconference only)

## Please register for the meeting by using the link below:

 $\underline{https://events.teams.microsoft.com/event/d0fafec0-a9eb-4bab-b4a8-fe561a4ffd26@34c95ba7-5ec6-4527-bc5e-b33b58104992}$ 

If you are calling in only through the webinar:

\*6 to Toggle mute/unmute and \*5 to raise/lower hand

After registering, you will receive a confirmation email containing information about joining the webinar.

## Agenda

Public Call In: 1-844-730-9010 Access code: 130 491 615#

Call to Order – Chair
Roll Call
8:00 am
8:05 am

3. Public Comment

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where \*\*new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

## **4.** Class review, discussion & vote.

| <b>AK Treatment Class</b> | Drug Class  | Status |
|---------------------------|---|--------|
| Respiratory/Allergy       | COPD Agents   | RED**  |
|                           | Glucocorticoids, Inhaled, Single Entity & Combination   | GREEN  |
|                           | Beta Agonists Bronchodilators, Long                     | GREEN  |
|                           | Beta Agonists Bronchodilators, Short                    | GREEN  |
|                           | Immunomodulators, Asthma                                | BLUE** |
|                           | Epinephrine, Self-Administered                          | RED**  |
|                           | Intranasal Rhinitis Agents                              | BLUE** |
|                           | Leukotriene Modifiers                                   | GREEN  |
|                           | Antihistamines, Minimally-Sedating                      | GREEN  |
| Immunological             | Cytokine & CAM Antagonists, Non-GI Indications          | RED**  |
|                           | Immunosuppressants, Oral                                | BLUE** |
| Dermatological            | Antipsoriatics Topical                                  | GREEN  |
|                           | Immunomodulators, Atopic Dermatitis                     | RED**  |
|                           | Topical Steroids – Low, Medium, High, Very High Potency | GREEN  |
|                           | Acne, Topical   | BLUE** |
| Ophthalmics               | Ophthalmic, Allergic Conjunctivitis                     | GREEN  |

<sup>\*\*</sup>New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

| Opi | ohthalmic, Antibiotics                     | GREEN  |
|-----|--|--------|
| Opl | ohthalmic, Antibiotics-Steroid Combination | GREEN  |
| Opl | ohthalmic, Anti-inflammatory               | BLUE** |
| Opl | ohthalmic, Glaucoma Agents                 | BLUE** |
| Op! | ohthalmic, Immunomodulators                | GREEN  |

- 5. **Break as needed** 15 minutes
- **6. Review minutes** from previous meeting
- 7. Comments from Committee Members or Chair
- 8. Adjourn

Next Meeting Date: April 18, 2025